fig3

Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma

Figure 3. Overview of cancer immunity cycle in post-locoregional therapy. Locoregional therapies generate cytotoxic CD8+ T cells that enhance the destruction of local and systemic cancers. Tumor destruction by locoregional therapy results in the release of several tumor antigens that can be processed by antigen-presenting cells and presented to naive T cells through major histocompatibility complex (MHC) class I molecules. The simultaneous release of DAMPs induces an adaptive immune response. Tumor-specific cytotoxic T cells were activated and proliferated in the lymph nodes, and then migrated into the circulatory system. APC: antigen-presenting cells; DAMPs: damage-associated molecular patterns; IFN-γ: interferon-gamma; Gzmb: granzyme B; TNF-α: tumor necrosis factor-alpha. Figure reprinted with copyright permission from reference[40].

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/